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OBJECTIVE — To describe a population-based two-step screening procedure for type 2
diabetes and to study the cardiovascular risk profile of the patients identified by the screening.
RESEARCH DESIGN AND METHODS — The first step of the screening procedure
consisted of the Symptom Risk Questionnaire (SRQ), and the second step was a fasting capillary
glucose measurement. In subjects with an SRQ score of6 and a capillary glucose level of5.5
mmol/l, an oral glucose tolerance test was performed.
RESULTS — A total of 11,679 inhabitants of the West-Friesland region of the Netherlands,
aged 50–75 years, were invited. Of the inhabitants, 9,169 (78%) responded, and, of those, 417
had previously diagnosed diabetes. The SRQ score was calculated for 7,736 participants, and
3,301 of those had a score of6. A total of 2,885 subjects (87.3%) attended for capillary glucose
measurement. Diagnostic testing was carried out in 509 participants, and we identified 217
diabetic patients. In these patients detected by screening, mean HbA1c was 6.7% (1.4). Hy-
pertension and high total cholesterol levels (5.0 mmol/l) were present in 70%, 33% had high
triglyceride (3.0 mmol/l) or low HDL cholesterol levels (1.0 mmol/l in men and1.1 mmol/l
in women), and 40% were obese (BMI 30 kg/m2).
CONCLUSIONS — The high response rate was the main feature of the screening by means
of the Symptom Risk Questionnaire and fasting capillary glucose measurement followed by
diagnostic testing. The 217 diabetic patients detected by the screening were characterized by
relatively low HbA1c levels and by a cardiovascular risk profile typical of diabetic patients.
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S creening for type 2 diabetes hasbeen promoted in the American Di-abetes Association guidelines and
the medical literature (1,2). The high
prevalence of undiagnosed diabetes (3,4),
the presence of diabetic complications at
the time of diagnosis (5), and the assump-
tion that early detection and treatment
will be beneficial have lead to these
recommendations.
Screening for type 2 diabetes can be
carried out in various ways. Population-
based or universal screening attempts to
screen every person in the entire popula-
tion or in an entire age-group. Selective or
targeted screening is directed at individu-
als with a high prevalence of risk factors.
Opportunistic screening consists of
screening people during their visits to, for
example, the general practitioner’s office
(6). Universal screening for type 2 diabe-
tes with oral glucose tolerance tests
(OGTTs) performed in the whole popula-
tion is burdensome because it is invasive
and time consuming. Targeted screening
with a noninvasive test for first selection,
followed by glucose testing in high-risk
individuals only, might be a more effi-
cient approach.
Studies on universal screening (7,8),
opportunistic screening in general prac-
tice (9), and targeted screening in general
practice (10) have been reported, but few
data exist on population-based targeted
screening for type 2 diabetes.
In this article, we report on a popula-
tion-based two-step screening procedure
and the cardiovascular risk profile of in-
dividuals identified as diabetic patients.
The two-step screening consisted of a
screening questionnaire (step 1) (Symp-
tom Risk Questionnaire [SRQ] [11]) and a
fasting capillary glucose sample (step 2)
followed by an OGTT.
RESEARCH DESIGN AND
METHODS
Study population
From 1998 to 2000, all inhabitants aged
50–75 years (n  11,679) and living in
three municipalities in the semi-rural re-
gion of West-Friesland, the Netherlands,
were invited to participate in the screen-
ing for type 2 diabetes.
Screening procedure
All individuals received an invitation with
a cover letter explaining the aim of the
study, an informed consent form, the
SRQ, a nonparticipation form, and an en-
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velope with prepaid postage. After 6
weeks, a reminder was sent to all people
who did not respond to the first invita-
tion. The first step of the screening con-
sisted of the completion of the SRQ,
which contains nine questions about age,
sex, BMI, family history of diabetes, fre-
quent thirst, use of antihypertensive med-
ication, shortness of breath, claudication,
and cycling. Each answer has a fixed
score, and the aggregate SRQ score is a
predictor of undiagnosed type 2 diabetes
(11). The cut point of six had optimal sen-
sitivity (66%) and specificity (70%) (pos-
itive predictive value 13%, negative
predictive value 97%) for diabetes, as de-
fined by the 1999 World Health Organi-
zation (WHO) diagnostic criteria
(A.M.W.S., J.M.D., unpublished data).
All participants with an SRQ score of 6
points were invited for the second step of
the screening, which consisted of a fasting
capillary blood glucose measurement.
Capillary glucose was measured in whole
blood samples with a Hemocue Blood
Glucose Analyzer, a portable photometric
system based on the glucose-dehydroge-
nase method (Hemocue Benelux, Oister-
wijk, the Netherlands). Intra- and
interassay coefficients of variation ranged
from 1.0 to 4.5% and from 2.4 to 4.2%,
respectively (12,13). In all individuals
with a capillary glucose level 5.5
mmol/l, which is the threshold for glucose
intolerance in the guidelines of the Dutch
College of General Practitioners (14), a
venous sample was drawn at the same oc-
casion. Participants with a capillary glu-
cose level 5.5 and 8.5 mmol/l had a
75-g OGTT within 2 weeks. Individuals
with a capillary glucose level 8.5
mmol/l did not have an OGTT because
their fasting levels were considered to be
too high. Therefore, only a second fasting
plasma glucose measurement was deter-
mined, and diagnosis was based on two
fasting plasma glucose measurements.
For all participants, 1999 WHO diagnos-
tic criteria were used: a fasting plasma
glucose level 7.0 mmol/l on two sepa-
rate occasions or a 2-h plasma glucose
level 11.1 mmol/l (15). Individuals
identified as having screening-detected
type 2 diabetes (SDM) were invited for an
extensive medical examination including
measurement of HbA1c, glucose, blood
lipids, anthropometry, and blood pres-
sure. The study was done at the Diabetes
Research Center in Hoorn, the Nether-
lands. All participants gave written in-
formed consent. The Ethics Committee of
the VU University Medical Center ap-
proved the study.
Measurements
Plasma glucose concentrations were as-
sessed by means of a glucose hexokinase
method (Boehringer Mannheim, Mann-
heim, Germany). HbA1c was determined
by ion-exchange high-performance liquid
chromatography with a Modular Diabetes
Mon i to r ing Sys t em (B io -Rad ,
Veenendaal, the Netherlands). Serum to-
tal cholesterol, HDL cholesterol, and trig-
lycerides were measured by enzymatic
techniques (Boehringer Mannheim). The
Friedewald formula was used to calculate
LDL cholesterol, except when the triglyc-
eride level was4.5 mmol/l. Weight and
height were measured with subjects bare-
foot, wearing only light clothes. Blood
pressure was calculated as the mean of
two measurements, performed in the sit-
ting position after 5 min of rest, using
a random-zero sphygmomanometer
(Hawksley-Gelman, Lancing, Sussex,
U.K.).
High cholesterol was present if serum
total cholesterol was 5.0 mmol/l. Low
HDL cholesterol was defined as HDL cho-
lesterol 1.0 mmol/l in men and HDL
cholesterol1.1 in women and high LDL
cholesterol as LDL cholesterol 3.0
mmol/l. High triglyceride was defined by
a triglyceride level 2.0 mmol/l (16). A
ratio of total cholesterol to HDL choles-
terol of 5 was considered to be high
(14). Obesity was defined as BMI 30
kg/m2 (17). Individuals were considered
to be hypertensive if they had a diastolic
blood pressure90 mmHg and/or a sys-
tolic blood pressure140 mmHg, and/or
if they were using antihypertensive med-
ication (18).
To study whether subgroups with dif-
ferent cardiovascular risk profiles could
be distinguished, we compared three sub-
groups. First, the patients with fasting
capillary glucose 8.5 mmol/l who did
not have an OGTT (non–OGTT-SDM)
were compared with patients who did
(OGTT-SDM). Next, within the group of
OGTT-SDM patients, we compared two
groups: the 2-h SDM group consisted of
patients for whom the 2-h value of the
OGTT was decisive for diagnosis because
they had none or only one elevated fasting
value. The mixed SDM group included
patients who had an OGTT and who had
two elevated fasting values. Some of these
patients also had an elevated 2-h value.
Statistical analysis
Groups were compared using the Stu-
dent’s t test for continuous variables, the
2 test for dichotomous variables, and the
Mann-Whitney U test for skewed vari-
ables. A P value of0.05 was considered
statistically significant. Triglycerides and
the SRQ score were presented as median
and interquartile range because of their
skewed distribution.
RESULTS
Two-step screening procedure
Response. Figure 1 shows the outline of
the stepwise screening procedure and the
number of participants in each step. A to-
tal of 11,679 individuals were invited. Of
those, 2,510 (22%) subjects did not re-
spond at all. There were 9,169 people
who sent back either the SRQ or the non-
participation form, resulting in a total re-
sponse of 78%. The 741 people who
returned the nonparticipation form were
significantly older than the participants of
the screening. Nonparticipants reported
various reasons: 28.5% checked the item
“I am certain that I do not have diabetes,”
15.7% checked “My health is already
monitored by a physician,” and 13.8%
checked “a recent blood glucose test was
OK.” In total, 417 previously diagnosed
diabetic patients completed the SRQ. The
SRQ was returned by a total of 8,011 non-
diabetic participants, but because of miss-
ing data (n 275), we calculated the SRQ
score for 7,736 participants. Of 3,301 in-
dividuals with an SRQ score of6 points,
2,885 participated in the fasting capillary
glucose measurement, and 570 had a glu-
cose level5.5 mmol/l. Of these, 38 had
a capillary glucose level8.5 mmol/l, and
no OGTT was performed, but two venous
fasting samples were taken. An OGTT was
carried out in 473 individuals. A total of
217 participants were identified by the
screening procedure as having type 2 di-
abetes. A physical examination was per-
formed in 195 patients.
Nonresponse. Table 1 shows the nonre-
sponse in various stages of the screening
procedure and diagnostic testing. The
nonresponse rate varied from 21% in the
very first step of the screening to 11% in
the diagnostic test. We found that the
nonresponders of the first screening step
(completion of the SRQ) were more likely
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to be men and to be younger than the
participants. The nonresponders for the
OGTT were older than participants.
Screening and diagnostic tests
Table 2 shows results of screening and
diagnostic tests of all SDM patients and
subgroups. The non–OGTT-SDM group
was younger than the OGTT-SDM group,
although not significantly so. The statisti-
cally significant differences in capillary
and fasting glucose levels between the
groups were a consequence of the sub-
group definition.
Clinical characteristics
Table 3 shows clinical characteristics of all
SDM patients and subgroups. Diabetic
dyslipidemia (high triglycerides and low
HDL cholesterol levels) was present in ap-
proximately one-third of all diabetic pa-
tients. High cholesterol and hypertension
were each present in 70% of diabetic
patients. The non–OGTT-SDM and
OGTT-SDM groups were comparable for
lipid levels, anthropometric measures,
and blood pressure. HbA1c levels were
significantly higher in the non–OGTT-
SDM group, but low HDL cholesterol in
men was significantly less frequent when
compared with the OGTT-SDM group.
Blood pressure in the 2-h SDM group was
significantly higher than that in the mixed
SDM group, but lipid levels were signifi-
cantly more favorable in 2-h SDM pa-
tients (low triglycerides and, in women,
no low HDL cholesterol). Fourteen indi-
viduals in the 2-h SDM group had isolated
postchallenge hyperglycemia. Compared
with the other SDM patients, they had sig-
nificantly lower glucose and HbA1c levels
and were significantly less obese.
CONCLUSIONS — Screening is di-
rected at the identification of patients in
the early stages of the disease. In the
present study, this was reflected by the
relatively low HbA1c levels in SDM pa-
tients. The prevalence of hypertension
and high total cholesterol was similar to
prevalence rates found in 15 patients in a
universal screening study (7) but was
higher compared with prevalence rates
from an opportunistic screening study
(9). In the latter study, however, the def-
initions of hypertension and high lipid
levels were not standardized for the whole
study population but varied between gen-
eral practices. In a study of diabetic pa-
tients recently diagnosed by their general
practitioner, the prevalence of hyperten-
sion was 61%, and abnormal lipids were
present in 78% of patients (19). In sum-
mary, prevalence of hypertension and
dyslipidemia in our study was of the same
magnitude or even slightly higher than
that reported in other screening studies
and in newly detected diabetic patients.
The prevalence rates of dyslipidemia,
obesity, and hypertension in our study
may be high because the SRQ includes
BMI and several cardiovascular items,
thus selecting a group of individuals with
an unfavorable cardiovascular risk pro-
file. One could argue that our screening
procedure identified diabetic patients
who might benefit most from early treat-
ment of dyslipidemia and hypertension.
The Heart Protection Study and the Cho-
lesterol and Recurrent Events trial have
already shown that type 2 diabetic pa-
tients do benefit from treatment of dyslip-
idemia in terms of reduction of lipid levels
(20,21) and reduction in the number of
major coronary events (21). Treatment of
hypertension in type 2 diabetic patients
has been demonstrated to reduce cardio-
vascular events and deaths related to
diabetes (22).
Figure 1—Outline of the stepwise population-based screening study. FPG, fasting plasma glu-
cose.
The Hoorn Screening Study
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The subgroup of non–OGTT-SDM
patients seemed to be patients in whom
diabetes was already in a more advanced
stage because they were relatively young,
had high HbA1c levels, and frequently re-
ported thirst and a family history of dia-
betes on the SRQ (SRQ data not shown).
Nevertheless, their cardiovascular risk
profile did not differ from that of patients
diagnosed by the OGTT. Because of the
symptoms and high fasting glucose val-
ues, we expect that these patients would
also have come to (rapid) clinical recog-
nition without the screening.
The 2-h SDM group would not have
been diagnosed if the OGTT had not been
performed. Apart from the higher preva-
lence of hypertension, this group did not
differ from the remaining SDM patients.
Moreover, in the Netherlands, 50% of
these patients would probably have been
tested again within 1 year because they
had one fasting plasma value in the dia-
betic range in addition to the elevated 2-h
value (14). The small group with isolated
postchallenge hyperglycemia and with
lower levels of fasting glucose, HbA1c, and
BMI would not have been identified at all
without the OGTT. In other words, with-
out the OGTT, we would have missed
only a small group of patients with a sim-
ilar cardiovascular risk profile. These re-
sults seem to imply that the OGTT added
relatively few cases and may not be re-
quired to identify the large majority of di-
abetic patients in this two-step screening
procedure.
The application of screening and di-
agnostic tests inevitably involves some
misclassification. We probably have
missed some individuals who did have di-
abetes but did not have the risk factors
included in the SRQ, i.e., the young, less
obese diabetic patients without a family
history of diabetes and without cardiovas-
cular symptoms. Because of the younger
age and absence of cardiovascular symp-
toms, one could speculate that this group
of missed patients would have a more fa-
vorable cardiovascular risk profile. The
total population prevalence of undiag-
nosed diabetes and the number of missed
diabetic patients can only be determined
by population screening. However, this
was not feasible. The difference between
the prevalence of screening-detected dia-
betes in a screening study and the preva-
lence of undiagnosed diabetes from a
population study might seem a good ap-
proximation of the number of missed pa-
tients. However, major differences
between populations in true diabetes
prevalence, quality of health care, and
routine detection of type 2 diabetes and
participation rates prohibit the compari-
son of results of different studies. The
same is true for the comparison of preva-
lence rates of screening-detected diabetes
among screening studies.
Engelgau et al. (6) stated in his review
of screening for type 2 diabetes that glu-
cose (invasive) tests performed better
than the screening questionnaires. Still,
Table 1—Nonresponse in various stages of the screening procedure and diagnostic testing
Screening step/diagnostic test Responders Nonresponders
Total population
n 11,679 —
Age (years) 59.6  7.1 —
Sex (% male) 50.9 —
SRQ
n (%) 7,736 (66) 2,510 (21)
Age (years) 59.4  6.9 58.8  7.0*
Sex (% male) 49.0 56.4*
Capillary measurement
n (%) 2,885 (87.3) 416 (12.6)
Age (years) 63.2  6.7 63.0  7.1
Sex (% male) 48.6 46.4
OGTT
n (%) 473 (88.9) 59 (11.1)
Age (years) 63.1  7.1 65.1  6.3
Sex (% male) 49.9 50.8
SRQ score 11 (9–14) 11 (9–14)
Capillary glucose (mmol/l) 6.1  0.6 6.1  0.5
Data are means  SD or median (interquartile range) unless otherwise indicated. *Nonresponders signifi-
cantly different from responders.
Table 2—Screening and diagnostic test results of screening-detected diabetic patients
All SDM Non–OGTT-SDM
OGTT-SDM
2-h SDM Mixed SDM
n 217 36 36 145
Age (years) 63.6  7.0 62.6  7.8 64.3  6.5 63.6  6.9
Sex (% male) 51.6 50.0 52.8 51.7
SRQ score 12 (9–16) 11 (9.25–15) 12 (9.3–14.8) 12 (9–17)
Fasting capillary glucose (mmol/l) 7.4  2.2 11.4  2.6* 5.9  0.3† 6.7  0.7
First FPG (mmol/l) 8.6  2.5 13.1  2.9* 6.8  0.4† 7.9  0.8
Second FPG (mmol/l) 7.8  0.9 12.9  2.7* 6.9  0.5† 8.1  0.9
2-h plasma glucose (mmol/l) 12.3  3.7 — 12.8  1.4 12.2  4.1
Data are means  SD or median (interquartile range) unless otherwise indicated. 2-h SDM, 2-h value of the OGTT decisive for diagnosis, with none or only one
elevated fasting value; FPG, fasting plasma glucose; mixed SDM group, two elevated fasting values or two elevated fasting and elevated 2-h values; non–OGTT-SDM,
patients with fasting capillary glucose 8.5 mmol/l, diagnosed on two fasting values, with no OGTT performed; OGTT-SDM, patients diagnosed on OGTT.
*Non–OGTT-SDM significantly different from OGTT-SDM; †2-h SDM significantly different from mixed SDM.
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we feel that in the selection of a screening
test, other aspects of screening should
prevail, for example, 1) the fact that
screening tends to involve a high number
of people relative to the number who ben-
efit eventually (23) and 2) that there is still
no convincing evidence for the benefits of
early diagnosis and treatment of type 2
diabetes (6,24).
In this context, we believe that a non-
invasive screening test should be the test
of choice. Naturally, this noninvasive
screening test should have good test char-
acteristics. We selected the SRQ, which
was developed in a Dutch population
and had the best performance of three
questionnaires (11).
Organization of the screening proce-
dure is likely to influence participation
rates. Nonresponse rates in other screen-
ing studies ranged from 65% in the
screening test (7) to 25% in diagnostic
testing (7,9). In our study, the nonre-
sponse was 22% in the first screening test
(SRQ) and 11% for the diagnostic test
(OGTT). Lawrence et al. (7) used a fasting
plasma glucose test as the first screening
tool. In contrast, in the present study,
only people with a higher risk of undiag-
nosed diabetes (high SRQ score) were
asked to go through the trouble of fasting
for a capillary glucose measurement. The
need to fast again for a diagnostic test was
also restricted to those with a high capil-
lary glucose level. We would like to stress
that high-risk individuals with a negative
OGTT result should be informed that
they do not have diabetes at this very mo-
ment but that they still have an elevated
future risk. In conclusion, our targeted
screening procedure is less of a burden for
its participants than universal screening
because the first screening test is nonin-
vasive, and further invasive diagnostic
testing is restricted to people at high risk
for undiagnosed diabetes. Targeted
screening might result in a cost advantage
as well because of the smaller number of
diagnostic tests, which will save money in
terms of time, personnel, and laboratory
costs.
Recently, O’Connor et al. (25) de-
scribed a stepwise screening within a
health management organization. The
first selection of the high-risk population
was based on information available in da-
tabases. Consequently, there was no ini-
tial loss due to nonresponse. However,
the participation rates for the subsequent
glucose tests were lower than in our pop-
ulation-based targeted screening, and
only a few patients were identified. The
quality of diabetes care within this health
management organization might have af-
fected the yield of screening, as was
shown by the high proportion of people
who were screened for diabetes in the pre-
vious year. The differences between these
two screening studies illustrate that com-
parisons of screening studies need to be
interpreted with caution.
The results of our study showed that
it was possible to carry out population-
based stepwise screening. We succeeded
in identifying 217 patients with type 2
diabetes, but we cannot say whether these
patients will benefit from their early iden-
tification in terms of health status or
Table 3—Clinical characteristics of screening-detected diabetic patients
All SDM Non–OGTT-SDM
OGTT-SDM
2-h SDM Mixed OGTT-SDM
n 195 33 29 133
HbA1c (%) 6.7  1.4 8.8  1.5* 5.8  0.5† 6.4  0.9
Cholesterol (mmol/l) 5.7  1.1 5.7  1.2 5.5  1.0 5.8  1.1
High cholesterol (%) 73.1 66.7 69.0 75.6
HDL cholesterol (mmol/l) 1.3  0.4 1.2  0.3 1.3  0.4 1.3  0.4
Low HDL
Women (%) 27.7 43.8 0† 28.8
Men (%) 35.4 11.8* 16.7 41.5
Cholesterol/HDL ratio 4.84  1.45 5.00  1.77 4.46  1.29 4.88  1.39
High cholesterol/HDL ratio (%) 35.9 36.4 27.6 44.3
LDL cholesterol (mmol/l) 3.57  0.96 3.59  0.96 3.46  0.81 3.59  0.99
High LDL (%) 77.2 74.2 71.4 79.2
Triglycerides (mmol/l) 1.7 (1.2–2.4) 1.6 (1.2–2.4) 1.4 (1.0–1.9)† 1.8 (1.3–2.4)
High triglycerides (%) 34.2 33.3 17.2† 38.2
Lipid-lowering therapy (%) 20.4 13.9 25.0 20.8
BMI (kg/m2) 29.8  5.3 29.9  6.4 28.4  4.1 30.1  5.3
Obesity (%) 40.0 36.4 31.0 42.9
Systolic blood pressure (mmHg) 141  18 141  19 148  15† 140  19
Diastolic blood pressure (mmHg) 86  10 88  11 88  8 85  9
Antihypertensive medication (%) 45.2 38.9 44.4 47.2
Hypertension (%) 69.6 69.4 75.0 68.3
Data are means  SD for continuous variables and median (interquartile range) for triglycerides. High total cholesterol: cholesterol 5.0 mmol/l; low HDL
cholesterol: HDL cholesterol1.0 mmol/l for men and HDL cholesterol1.1 for women; high LDL cholesterol: LDL cholesterol3.0 mmol/l; high triglycerides:
triglycerides2.0 mmol/l; high cholesterol/HDL cholesterol ratio5. Obesity: BMI30 kg/m2. Hypertension: diastolic blood pressure90 mmHg, systolic blood
pressure 140 mmHg, and/or use of antihypertensive medication. 2-h SDM group, 2-h value of the OGTT decisive for diagnosis, with none or only one elevated
fasting value; mixed SDM group, two elevated fasting values or two elevated fasting and elevated 2-h values; non–OGTT SDM, patients with fasting capillary glucose
8.5 mmol/l, diagnosed on two fasting values, with no OGTT performed; OGTT-SDM, patients diagnosed on OGTT. *High fasting SDM significantly different from
OGTT-SDM; †2-h SDM significantly different from mixed SDM.
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whether the screening is cost-effective.
Future screening studies should focus on
the quantification of possible benefits of
early detection followed by early treat-
ment.
In conclusion, our results show that
stepwise population screening by means
of the SRQ and a fasting capillary glucose
measurement followed by diagnostic test-
ing was an acceptable and practical
method of screening for type 2 diabetes.
The diabetic patients detected by the
screening were characterized by relatively
low HbA1c levels and a cardiovascular risk
profile typical of diabetic patients.
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